

Wei-Jia Fang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2322257/publications.pdf>

Version: 2024-02-01

91
papers

3,075
citations

236833

25
h-index

206029

48
g-index

93
all docs

93
docs citations

93
times ranked

4153
citing authors

#	ARTICLE	IF	CITATIONS
1	Construction of TME and Identification of crosstalk between malignant cells and macrophages by SPP1 in hepatocellular carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 121-136.	2.0	43
2	Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy. , 2022, 10, e003133.		20
3	Clinical outcomes associated with tislelizumab in patients (pts) with advanced hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (SOR) or lenvatinib (LEN) in RATIONALE-208.. <i>Journal of Clinical Oncology</i> , 2022, 40, 420-420.	0.8	5
4	NKG2D discriminates diverse ligands through selectively mechano-regulated ligand conformational changes. <i>EMBO Journal</i> , 2022, 41, e107739.	3.5	21
5	Molecular Subgroups of Intrahepatic Cholangiocarcinoma Discovered by Single-Cell RNA Sequencing Assisted Multiomics Analysis. <i>Cancer Immunology Research</i> , 2022, 10, 811-828.	1.6	21
6	Clinical outcomes in patients (pts) with previously treated advanced hepatocellular carcinoma (HCC) experiencing hepatitis B virus (HBV) DNA increases during tislelizumab (TIS) treatment in RATIONALE-208.. <i>Journal of Clinical Oncology</i> , 2022, 40, e16181-e16181.	0.8	0
7	Health-related quality of life (HRQoL) impact of pembrolizumab (pembro) plus best supportive care (BSC) versus placebo (PBO) plus BSC as second-line (2L) therapy in patients (pts) in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4088-4088.	0.8	9
8	Clinical outcomes associated with tislelizumab in patients (pts) with advanced hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (SOR) or lenvatinib (LEN) in RATIONALE-208.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4072-4072.	0.8	3
9	TOD-CUP: a gene expression rank-based majority vote algorithm for tissue origin diagnosis of cancers of unknown primary. <i>Briefings in Bioinformatics</i> , 2021, 22, 2106-2118.	3.2	12
10	Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels tumour heterogeneity plus M2-like tumour-associated macrophage infiltration and aggressiveness in TNBC. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 189-202.	2.0	82
11	Phase I trial of fourth-generation chimeric antigen receptor T-cells targeting glypican-3 for advanced hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4088-4088.	0.8	11
12	Retrospective pilot study of regorafenib combined with ICIs in the third-line treatment of advanced colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, e15582-e15582.	0.8	2
13	Clonal Evolution Dynamics in Primary and Metastatic Lesions of Pancreatic Neuroendocrine Neoplasms. <i>Frontiers in Medicine</i> , 2021, 8, 620988.	1.2	4
14	Dual-targeted therapy with pyrotinib and trastuzumab for HER2-positive advanced colorectal cancer: Preliminary results from a multicenter phase 2 trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, e15554-e15554.	0.8	9
15	Editorial: Immunotherapy in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 698515.	1.3	0
16	GdClean: removal of Gadolinium contamination in mass cytometry data. <i>Bioinformatics</i> , 2021, 37, 4787-4792.	1.8	2
17	Depiction of the genomic and genetic landscape identifies CCL5 as a protective factor in colorectal neuroendocrine carcinoma. <i>British Journal of Cancer</i> , 2021, 125, 994-1002.	2.9	14
18	Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 559-568.	3.7	121

#	ARTICLE	IF	CITATIONS
19	Impact of <i>UGT1A1</i> genotype on the efficacy and safety of irinotecan-based chemotherapy in metastatic colorectal cancer. <i>Cancer Science</i> , 2021, 112, 4669-4678.	1.7	8
20	Signaling pathway perturbation analysis for assessment of biological impact of cigarette smoke on lung cells. <i>Scientific Reports</i> , 2021, 11, 16715.	1.6	5
21	Emerging treatment evolutions and integrated molecular characteristics of biliary tract cancers. <i>Cancer Science</i> , 2021, 112, 4819-4833.	1.7	4
22	Large-scale identification of extracellular plant miRNAs in mammals implicates their dietary intake. <i>PLoS ONE</i> , 2021, 16, e0257878.	1.1	6
23	Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma. <i>Theranostics</i> , 2021, 11, 3489-3501.	4.6	35
24	Interleukin-33 as an early predictor of cetuximab treatment efficacy in patients with colorectal cancer. <i>Cancer Medicine</i> , 2021, 10, 8338-8351.	1.3	8
25	414...A randomized phase II study of systemic therapy plus WeiLeShu (WLS) versus systemic therapy alone in patients with metastatic colorectal cancer (mCRC). , 2021, 9, A445-A445.		0
26	412...CAMrelizumab and apatiniB combined with chemotherapy (mFOLFOX6) as neoadjuvant therapy for locally advanced right-sided colon cancer (AMBITION). , 2021, 9, A443-A443.		1
27	Case Report: Effectiveness of Targeted Treatment in a Patient With Pancreatic Cancer Harboring PALB2 Germline Mutation and KRAS Somatic Mutation. <i>Frontiers in Medicine</i> , 2021, 8, 746637.	1.2	4
28	Residual refinement for interactive skin lesion segmentation. <i>Journal of Biomedical Semantics</i> , 2021, 12, 22.	0.9	2
29	Analysis of the molecular nature associated with microsatellite status in colon cancer identifies clinical implications for immunotherapy. , 2020, 8, e001437.		57
30	Effect of Reduced-Dose Capecitabine Plus Cetuximab as Maintenance Therapy for <i>RAS</i> Wild-Type Metastatic Colorectal Cancer. <i>JAMA Network Open</i> , 2020, 3, e2011036.	2.8	6
31	Whole-exome sequencing reveals potential mechanisms of drug resistance to FGFR3-TACC3 targeted therapy and subsequent drug selection: towards a personalized medicine. <i>BMC Medical Genomics</i> , 2020, 13, 138.	0.7	4
32	Nutrition and metabolism status alteration in advanced hepatocellular carcinoma patients treated with anti-PD-1 immunotherapy. <i>Supportive Care in Cancer</i> , 2020, 28, 5569-5579.	1.0	15
33	Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial. <i>Journal of Hematology and Oncology</i> , 2020, 13, 47.	6.9	84
34	Dynamic alterations of genome and transcriptome in KRAS G13D mutant CRC PDX model treated with cetuximab. <i>BMC Cancer</i> , 2020, 20, 416.	1.1	5
35	Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review. <i>Frontiers in Immunology</i> , 2020, 11, 1037.	2.2	55
36	Ultra-stable Biomembrane Force Probe for Accurately Determining Slow Dissociation Kinetics of PD-1 Blockade Antibodies on Single Living Cells. <i>Nano Letters</i> , 2020, 20, 5133-5140.	4.5	19

#	ARTICLE	IF	CITATIONS
37	SCAU-Net: Spatial-Channel Attention U-Net for Gland Segmentation. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 670.	2.0	62
38	Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 571-580.	5.1	373
39	Disease characteristics and treatment patterns of Chinese patients with metastatic colorectal cancer: a retrospective study using medical records from China. <i>BMC Cancer</i> , 2020, 20, 131.	1.1	25
40	Treatment patterns and direct medical costs of metastatic colorectal cancer patients: a retrospective study of electronic medical records from urban China. <i>Journal of Medical Economics</i> , 2020, 23, 456-463.	1.0	23
41	Edge Intelligence: The Confluence of Edge Computing and Artificial Intelligence. <i>IEEE Internet of Things Journal</i> , 2020, 7, 7457-7469.	5.5	480
42	Development, Validation and Comparison of Artificial Neural Network Models and Logistic Regression Models Predicting Survival of Unresectable Pancreatic Cancer. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 196.	2.0	24
43	Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4507-4507.	0.8	24
44	A phase III study of comparing FOLFOX+/-bevacizumab with FOLFOX+/-bevacizumab+ high-dose intravenous vitamin C as first-line therapy in patients with advanced colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS4115-TPS4115.	0.8	1
45	Genomic signatures reveal DNA damage response deficiency in colorectal cancer brain metastases. <i>Nature Communications</i> , 2019, 10, 3190.	5.8	64
46	Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma. , 2019, 7, 193.		304
47	Expert consensus on multidisciplinary therapy of colorectal cancer with lung metastases (2019) Tj ETQq1 1 0.784314 rgBT /Overlock 100 6.9 69		
48	Carcinoma of Unknown Primary with <i>EML4-ALK</i> Fusion Response to <i>ALK</i> Inhibitors. <i>Oncologist</i> , 2019, 24, 449-454.	1.9	12
49	Advantage of Next-Generation Sequencing in Dynamic Monitoring of Circulating Tumor DNA over Droplet Digital PCR in Cetuximab Treated Colorectal Cancer Patients. <i>Translational Oncology</i> , 2019, 12, 426-431.	1.7	35
50	Antibiotics and immunotherapy in gastrointestinal tumors: Friend or foe?. <i>World Journal of Clinical Cases</i> , 2019, 7, 1253-1261.	0.3	13
51	Sequencing of different targeted therapies in management of KRAS wild-type metastatic colorectal cancer: A meta-analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, 679-679.	0.8	0
52	Simultaneous detection and characterization of toxigenic <i>Clostridium difficile</i> directly from clinical stool specimens. <i>Frontiers of Medicine</i> , 2018, 12, 196-205.	1.5	3
53	A naive Bayes algorithm for tissue origin diagnosis (TOD-€Bayes) of synchronous multifocal tumors in the hepatobiliary and pancreatic system. <i>International Journal of Cancer</i> , 2018, 142, 357-368.	2.3	16
54	A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin. <i>British Journal of Cancer</i> , 2018, 119, 291-295.	2.9	52

#	ARTICLE	IF	CITATIONS
55	Molecular Epidemiology of Clostridium difficile Infection in Hospitalized Patients in Eastern China. Journal of Clinical Microbiology, 2017, 55, 801-810.	1.8	86
56	Cetuximab Enhanced the Cytotoxic Activity of Immune Cells during Treatment of Colorectal Cancer. Cellular Physiology and Biochemistry, 2017, 44, 1038-1050.	1.1	35
57	Predictive value of preoperative peripheral blood neutrophil/lymphocyte ratio for lymph node metastasis in patients of resectable pancreatic neuroendocrine tumors: a nomogram-based study. World Journal of Surgical Oncology, 2017, 15, 108.	0.8	32
58	Identifying the clonal origin of synchronous multifocal tumors in the hepatobiliary and pancreatic system using multi-omic platforms. Oncotarget, 2017, 8, 5016-5025.	0.8	9
59	Gemcitabine and S-1 as first-line chemotherapy in patients with metastatic or advanced pancreatic cancer.. Journal of Clinical Oncology, 2017, 35, 492-492.	0.8	1
60	Clostridium difficile colonization in preoperative colorectal cancer patients. Oncotarget, 2017, 8, 11877-11886.	0.8	33
61	Abstract 539: MAEL promotes colorectal cancer cell growth and migration by activating EGFR pathway. , 2017, , .		0
62	Genome Sequence and Analysis of <i>Peptoclostridium difficile</i> Strain ZJCDC-S82. Evolutionary Bioinformatics, 2016, 12, EBO.S32476.	0.6	9
63	Over-expression of cathepsin B in hepatocellular carcinomas predicts poor prognosis of HCC patients. Molecular Cancer, 2016, 15, 17.	7.9	69
64	Gastrointestinal bleeding due to pancreatic metastasis of non-small cell lung cancer: A report of two cases and a literature review. Oncology Letters, 2015, 9, 2041-2045.	0.8	4
65	Neurokinin-2 receptor polymorphism predicts lymph node metastasis in colorectal cancer patients. Oncology Letters, 2015, 9, 2003-2006.	0.8	5
66	A phase II study of biweekly S-1 and paclitaxel (SPA) as first-line chemotherapy in patients with metastatic or advanced gastric cancer. Cancer Chemotherapy and Pharmacology, 2015, 76, 197-203.	1.1	7
67	Real-Time Cell Analysis for Monitoring Cholera Toxin-Induced Human Intestinal Epithelial Cell Response. Current Microbiology, 2015, 70, 536-543.	1.0	6
68	The prognostic value of plasma soluble CD40 ligand levels in patients with nasopharyngeal carcinoma. Clinica Chimica Acta, 2015, 447, 66-70.	0.5	8
69	Circulating and tumor-infiltrating Tim-3 in patients with colorectal cancer. Oncotarget, 2015, 6, 20592-20603.	0.8	61
70	Aberrant Expression of HOXA5 and HOXA9 in AML. Asian Pacific Journal of Cancer Prevention, 2015, 16, 3941-3944.	0.5	9
71	Prognostic Value of Perineural Invasion in Gastric Cancer: A Systematic Review and Meta-Analysis. PLoS ONE, 2014, 9, e88907.	1.1	102
72	â€˜Druggableâ€™ alterations detected by Ion Torrent in metastatic colorectal cancer patients. Oncology Letters, 2014, 7, 1761-1766.	0.8	10

#	ARTICLE	IF	CITATIONS
73	Clostridium difficile carriage in hospitalized cancer patients: a prospective investigation in eastern China. BMC Infectious Diseases, 2014, 14, 523.	1.3	25
74	A DNA minor groove binder shows high effectiveness as a quencher for FRET probes. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 3956-3960.	1.0	4
75	Biweekly S-1 plus paclitaxel (SPA) as second-line chemotherapy after failure from fluoropyrimidine and platinum in advanced gastric cancer: a phase II study. Cancer Chemotherapy and Pharmacology, 2014, 74, 503-509.	1.1	5
76	Sequential treatment of icotinib after first-line pemetrexed in advanced lung adenocarcinoma with unknown EGFR gene status. Journal of Thoracic Disease, 2014, 6, 958-64.	0.6	9
77	Complete remission of platinum-refractory primary Fallopian tube carcinoma with third-line gemcitabine plus cisplatin: A case report and review of the literature. Oncology Letters, 2013, 5, 1601-1604.	0.8	4
78	Capecitabine but not 5-FU worsened hepatosplenomegaly and liver function when used with oxaliplatin and cetuximab as first-line treatment in K-ras wild-type metastatic colorectal cancer.. Journal of Clinical Oncology, 2013, 31, e14530-e14530.	0.8	0
79	“Druggable” alterations detected by ion torrent in metastasis colorectal cancer patients.. Journal of Clinical Oncology, 2013, 31, e22192-e22192.	0.8	0
80	Characteristic CYP2A6 genetic polymorphisms detected by TA cloning-based sequencing in Chinese digestive system cancer patients with S-1 based chemotherapy. Oncology Reports, 2012, 27, 1606-10.	1.2	3
81	Prognostic significance of vascular endothelial growth factor immunohistochemical expression in gastric cancer: a meta-analysis. Molecular Biology Reports, 2012, 39, 9473-9484.	1.0	46
82	Hand-foot syndrome in a patient with metastatic lung adenocarcinoma induced by high-dose icotinib: A case report and review of the literature. Oncology Letters, 2012, 4, 1341-1343.	0.8	4
83	Rapid molecular identification of Listeria species by use of real-time PCR and high-resolution melting analysis. FEMS Microbiology Letters, 2012, 330, 72-80.	0.7	33
84	Genome-wide Analysis of Aberrant DNA Methylation for Identification of Potential Biomarkers in Colorectal Cancer Patients. Asian Pacific Journal of Cancer Prevention, 2012, 13, 1917-1921.	0.5	30
85	T85C polymorphisms of the dihydropyrimidine dehydrogenase gene detected in gastric cancer tissues by high-resolution melting curve analysis. Turkish Journal of Gastroenterology, 2012, 23, 652-657.	0.4	0
86	New EGFR-TKI: a case report of recurrent lung adenocarcinoma successfully treated with icotinib. Tumori, 2012, 98, e102-4.	0.6	2
87	Celastrol induces apoptosis in non-small-cell lung cancer A549 cells through activation of mitochondria- and Fas/FasL-mediated pathways. Toxicology in Vitro, 2011, 25, 1027-1032.	1.1	85
88	Retroperitoneal primary mucinous adenocarcinoma: A case report. Oncology Letters, 2011, 2, 633-636.	0.8	6
89	Clinical significance of K-ras and BRAF mutations in Chinese colorectal cancer patients. World Journal of Gastroenterology, 2011, 17, 809.	1.4	48
90	A Phase II Trial of Oxaliplatin, Folinic Acid, and 5-Fluorouracil (FOLFOX4) as First-Line Chemotherapy in Advanced Colorectal Cancer: A China Single-Center Experience. Cancer Investigation, 2007, 25, 599-605.	0.6	2

#	ARTICLE	IF	CITATIONS
91	Characterization of Genomic Alterations in Colorectal Liver Metastasis and Their Prognostic Value. <i>Frontiers in Cell and Developmental Biology</i> , 0, 9, .	1.8	6